When he approached us, he was looking for an investor who would understand rare diseases the way he did. His vision was to build a mission-driven company to treat rare and ultra-rare genetic diseases—all the way from concept to globally-approved drugs.
The mutual trust between us was strong from the start. Emil demonstrated great leadership recruiting the team and hunting for drugs. Together we had to be opportunistic, and willing to go off-script and embrace a vision larger than “VC-101”-focused company building. We had to have the ability to support product acquisition, collaborations, and the additional investment that effort implied. Most small companies don’t have four clinical programs just three years after being founded. Ultragenyx did.
And in 2017—just six years in—Ultragenyx launched Mepsevii, a globally-approved therapy for Sly’s disease, an extremely severe and rare genetic disease that had remained untreated since it was first identified in 1972. 2018 saw the global approval of Crysvita for the rare bone disease X-linked hypophosphatemia.
It was a privilege for us to support Emil right from the beginning of the Ultragenyx story.
“F-Prime was a great partner, they understood the vision we had at Ultragenyx, and helped us make it a reality.”
—Emil Kakkis, CEO
Sana Biotechnology, Inc. (NASDAQ: SANA) is focused on creating and delivering engineered cells as medicine for patients. We are a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and changes how we approach treating disease.
Genomics plc’s vision is to use genomic insights to transform the drug discovery industry by getting better drugs developed more quickly and targeted at the right group of patients.
Brian joined F-Prime in 2018 and focuses primarily on investments in the biopharmaceutical and medical technology sectors. Prior to joining F-Prime, Brian was an engagement manager at McKinsey and Company, where he advised pharmaceutical and medical technology companies on business development, R&D, and strategy topics.
Brian holds a PhD in immunology from Yale University and received his B.S. in biochemistry from the University of Notre Dame.
NodThera is a biotech engaged in innate immune/inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases.
Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.
b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide.
Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. Nebula Genomics was acquired by ProPhase Labs in 2021.
Benchling is the industry-leading software platform for life science R&D. Purpose-built for biologics, Benchling combines an Electronic Lab Notebook (ELN), Laboratory Information Management System (LIMS), and a molecular biology design suite into a single, unified, cloud-based platform. It’s trusted by over 200,000 scientists — from pioneering academics and high-growth startups to all of the world’s top 50 biopharma companies.
Farapulse is a medical device company developing a novel approach to treating a range of arrhythmias using pulsed electric field. Farapulse was acquired by Boston Scientific in 2021.